Short Bowel syndrome and Gattex
CLINICAL APPLICATION OF TEDUGLUTIDE
Teduglutide (Gattex, Shire Pharmaceuticals, Inc., North Reading, Massachusetts) was approved by
the FDA in December 2012 for use in adult patients with SBS dependent on parenteral support [141.
Teduglutide has also been approved by the European Medicines Agency for SBS patients as a long-
term aid to PN weaning (Revestive). The recommended dose is mg/kg/day administered by
subcutaneous injection. A 50% dosage reduction is recommended in patients with renal impairment
(creatinine clearance less than 50 mL/min). Teduglutide is supplied in a sterile, single-use glass vial
containing 5.0 mg of teduglutide as a white, lyophilized powder to be reconstituted with 0.5 mL
of sterile water for subcutaneous injection. The average annual cost for teduglutide administration
CLINICAL APPLICATION OF TEDUGLUTIDE
Teduglutide (Gattex, Shire Pharmaceuticals, Inc., North Reading, Massachusetts) was approved by
the FDA in December 2012 for use in adult patients with SBS dependent on parenteral support [141.
Teduglutide has also been approved by the European Medicines Agency for SBS patients as a long-
term aid to PN weaning (Revestive). The recommended dose is mg/kg/day administered by
subcutaneous injection. A 50% dosage reduction is recommended in patients with renal impairment
(creatinine clearance less than 50 mL/min). Teduglutide is supplied in a sterile, single-use glass vial
containing 5.0 mg of teduglutide as a white, lyophilized powder to be reconstituted with 0.5 mL
of sterile water for subcutaneous injection. The average annual cost for teduglutide administration
No comments:
Post a Comment